Clinical Trial Update: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating MRD-guided treatment after almonertinib induction therapy for EGFRm+ stage III non-small cell lung cancer within an MDT dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Lung Cancer | Phase 3 | Status: RECRUITING